Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Time to Buy?

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up prior to trading on Friday . The stock had previously closed at $17.49, but opened at $18.68. Daiichi Sankyo shares last traded at $18.19, with a volume of 59,723 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Daiichi Sankyo Price Performance

The company has a 50-day moving average of $17.40 and a 200-day moving average of $17.29. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The stock has a market cap of $33.81 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 2.41 and a beta of -0.11.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%.The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities research analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.